Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jenna Rhoton

Physician Assistant Ogden, UT Physician Assistant

NPI 1134769375 CMS profile 10507371

4650 Harrison Blvd, Ogden, UT 84403

Open in the dashboard

General payments

$28,881

584 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jenna Rhoton of Ogden, UT is reported in the CMS Open Payments database as having received $28,881 across 584 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,719 113
2024 General $8,069 140
2023 General $7,736 137
2022 General $6,405 125
2021 General $1,952 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenna Rhoton
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jenna Rhoton were reported at $4,719. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jenna Rhoton Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,952 $132 $37–$438 $132
2022 $6,405 $155 $48–$522 $149
2023 $7,736 $167 $52–$557 $160
2024 $8,069 $178 $55–$600 $164
2025 $4,719 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $16,931 230 payments
  2. Biohaven Pharmaceutical Holding Company Ltd. $4,588 18 payments
  3. Biohaven Pharmaceuticals, Inc. $912 5 payments
  4. Novartis Pharmaceuticals Corporation $444 19 payments
  5. Teva Pharmaceuticals USA, Inc. $436 26 payments
  6. Celgene Corporation $401 26 payments
  7. SK Life Science, Inc. $374 14 payments
  8. Biogen, Inc. $372 18 payments
  9. Amgen Inc. $318 10 payments
  10. Genzyme Corporation $295 13 payments
  11. Other $3,811 205 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $18,015 21 payments
  2. Food and Beverage $10,013 556 payments
  3. Consulting Fee $800 1 payment
  4. Travel and Lodging $40 5 payments
  5. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $11,141 126 payments
  2. QULIPTA $10,958 89 payments
  3. NURTEC ODT $5,500 23 payments
  4. ZEPOSIA $499 28 payments
  5. BOTOX Botox Therapeutic $432 43 payments
  6. KESIMPTA $407 17 payments
  7. TYSABRI $325 15 payments
  8. BOTOX Hyperhydrosis $257 20 payments
  9. AJOVY $247 18 payments
  10. AUBAGIO $225 10 payments
  11. Other $4,908 267 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

688

Median for Physician Assistant: 241

Drug cost

$191,656

Median for Physician Assistant: $4,110

Branded share of claims

35.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 44 $44,507
Aimovig Autoinjector Erenumab-Aooe Brand 51 $35,955
Botox Onabotulinumtoxina Brand 20 $26,365
Qulipta Atogepant Brand 23 $24,723
Ajovy Autoinjector Fremanezumab-Vfrm Brand 27 $24,633
Emgality Pen Galcanezumab-Gnlm Brand 30 $23,376
Oxcarbazepine Generic 22 $1,728
Levetiracetam Generic 51 $1,455
Pregabalin Generic 21 $1,375
Lacosamide Generic 23 $1,085

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$68,462

Of which drugs: $49,925

Medicare patients

81

Average age 70

Services billed

10,442

54 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 48%
Depression 42%
Chronic kidney disease 35%
Diabetes 31%
Atrial fibrillation 21%
Ischemic heart disease 20%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 17 10,100 $49,916

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $3,588
$3,588 — —
QULIPTA
  • AbbVie, Inc. $2,776
$2,776 23 —
ZEPOSIA
  • Celgene Corporation $169
  • E.R. Squibb & Sons, L.L.C. $24
$193 — —
BOTOX
  • AbbVie, Inc. $154
$155 20 10,100
KESIMPTA
  • Novartis Pharmaceuticals Corporation $120
$120 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

584 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record